UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: December 31, 2007

(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

386-418-4018

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

On December 31, 2007, Dr. Robert Zahradnik resigned as Chief Executive Officer, President and a director of the Company as a result of his retirement.

Effective December 31, 2007, Dr. Ronald P. Evens, a Director, has been named President and Chief Executive Officer of the Company replacing Dr. Zahradnik. Dr. Evens will also continue to serve on the Company’s Board of Directors. Dr. Evens has served as Director since June 15, 2007. He is also President and CEO of MAPS 4 Biotec, a biotechnology consulting company in Jacksonville, Florida, and is Clinical Professor, University of Florida, College of Pharmacy. Prior to that, Dr. Evens has had a distinguished industrial career, including thirteen years at Amgen, a leading human therapeutics biotechnology company, where he served as Senior Director and Head of Professional Services. Prior to that, he spent six years at Bristol-Myers, a global pharmaceutical company, where he was Associate Director, Clinical Research & Medical Services. He has written/edited the book, “Drug & Biological Development, From Molecule to Product & Beyond” (Springer, 2007), and has served on twelve professional and medical Boards of Directors or Advisory Boards.

Dr. Evens employment is “at will” and may be terminated by him or the Company upon 30 days written notice. The expected tenure of his employment is until a permanent chief executive officer is successfully recruited and retained in 2008. The Company has agreed to a compensation arrangement with Dr. Evens and the material terms include monthly compensation of $14,583.33 or an annual salary of $175,000.00. Additionally, Dr. Evens will be awarded 30,000 stock options at an exercise price of $0.44 which will vest at the time of hiring a permanent chief executive officer.

Concurrently with the above, the Company also announced the appointment of Richard T. Welch, as an independent director to the Board of Directors to fill the vacancy left by Dr. Zahradnik. Rick Welch is President of Welch Business Solutions and Consulting, LLC in Tampa, Florida, and has served as a Director and CFO for several healthcare companies, including Orthopedic Development Corporation, Albiorex, LLC, Medi-Spa’s of America, Inc., and Vision Twenty-One. Previously, he served as executive vice-president of finance and administration, and earlier as CFO, for Sports and Recreation, Inc. Rick is also a CPA and received his BS in management and accounting from Louisiana State University. In connection with his appointment, Mr. Welch was awarded 65,000 stock options at an exercise price of $0.44 which vests immediately.

Mr. Welch will be expected to serve on the Company’s audit committee to replace Dr. Evens on such committee as a result of Dr. Evens no longer qualifying as an independent director.

On January 3, 2008, Derek Hennecke was appointed to serve on the Board of Directors as an independent director bringing the Board to four directors of which two members are independent directors. Derek is President and CEO of Xcelience, a pharmaceutical formulation development and contract manufacturing company headquartered in Tampa, FL. Prior to this, he was VP and GM of Pharmaceutics and Biopharmaceuticals of MDS Pharma Sciences and was responsible for the business and operations of CRO formulation development. Before joining MDS, he held various drug development management positions in Canada, Egypt, The Netherlands and Mexico. In connection with his appointment, Mr. Hennecke was awarded 65,000 stock options at an exercise price of $0.41 which will vest immediately. Mr. Hennecke will be expected to serve on the audit committee.

A copy of the January 2, 2008 press release announcing the retirement of Dr. Zahradnik and the appointment of Dr. Evens as chief executive officer and president and the appointment of Richard Welch as a director is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBITS